Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer-Reference-Cited by-同舟云学术

Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer

Published:2021-06 Issue:6 Volume:43 Page:1107-1115
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Bao Kunxi,Li Xiaobing,He Xiaojing,Jian Lingyan

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancersin 185 countries[J];Bray;CA Cancer J Clin,2018

2. Epidemiology and burden of pancreatic cancer.[J];Maisonneuve;Presse Med,2019

3. Pancreatic cancer: diagnosis and treatments[J];Li;Tumor Biol,2015

4. Pancreatic cancer: yesterday, today and tomorrow[J];Ansari;Future Oncol,2016

5. Correction: Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States[J];Rahib;Cancer Res,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tetrahydrobenzothiophene derivatives ameliorate Mia PaCa-2 cell progression and induces apoptosis via inhibiting EGFR2 tyrosine kinase signal;Bioorganic Chemistry;2024-02

2. Synthesis and Structure–Activity Analysis of Icaritin Derivatives as Potential Tumor Growth Inhibitors of Hepatocellular Carcinoma Cells;Journal of Natural Products;2023-02-06

3. Xijiao Dihuang decoction relieves the erlotinib-induced dermatitis;Experimental Cell Research;2023-02

4. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present;Biomolecules;2022-06-10

5. Erlotinib added to gemcitabine not cost effective for pancreatic cancer;PharmacoEconomics & Outcomes News;2021-06